AC Immune SA ACIU
Regular-session close
After hours · Nov 20, 6:35 PM ET
- YTD
- -37.90%
- 1 year
- -32.99%
5D -0.12 (-5.41%)
- Market cap
- 193.88M
- Revenue (ttm)
- 40.97M
- Profit margin
- -97.29%
- EPS (ttm)
- -0.44
- Shares out
- 98.94M
- Forward P/E
- -10.72
- YTD return
- -37.90%
- 1-year return
- -32.99%
- 50-day average
- 3.11
- Volume
- 298.38K
- Avg volume
- 201.06K
- Open
- 2.13
- Previous close
- 2.13
- Day's range
- 1.93 – 2.15
- 52-week range
- 1.95 – 3.70
- Beta
- 1.28
- Analysts
- Strong Buy
- Price target
- 10.01 (+413.1%)
Key statistics
- 200-day average
- 3.32
- Enterprise value
- 112.76M
- Price / sales
- 6.47
- Price / book
- 2.06
- Free cash flow
- 49.50M
- Total cash
- 157.90M
- Total debt
- 3.08M
- Return on equity
- -31.16%
- Short % of float
- 1.93%
Fundamental scorecard
6 of 25 checks passed on ACIU’s reported financials
6of 25 checks passed
- Value 1 of 5
- Growth 2 of 5
- Profitability 1 of 5
- Financial health 2 of 5
- Dividend No data
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2024 | Sep 1, 2024 | -0.22 | 0.06 | +0.28 | +127.27% |
| Aug 6, 2024 | Jun 1, 2024 | 0.42 | -0.25 | -0.67 | -159.52% |
| May 13, 2024 | Mar 1, 2024 | -0.15 | -0.21 | -0.06 | -40.00% |
| Mar 14, 2024 | Dec 1, 2023 | -0.07 | -0.06 | +0.01 | +14.29% |
| Nov 3, 2023 | Sep 1, 2023 | 0.00 | -0.20 | — | — |
| Aug 4, 2023 | Jun 1, 2023 | -0.22 | -0.22 | 0.00 | 0.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 6, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 18, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 31, 2024 | BTIG | init | — | Buy |
| Mar 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 13, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
About AC Immune SA
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It is developing Crenezumab, a humanized, conformation-specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti-Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD. The company is also developing ACI-24.060 for the treatment of down syndrome-related AD; ACI-7104.056, to treat Parkinson's disease; and ACI-35.030, designs to stimulate a patient's immune system to produce antibodies against pathological phosphorylated Tau. In addition, it is developing diagnostic programs, consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative disease. Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD and NeuroOrphan Tauopathies. Additionally, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Switzerland
- Website
- acimmune.com
News
AC Immune to Present at Jefferies Global Healthcare Conference 2026
AC Immune (ACIU) Reports Q3 Loss, Beats Revenue Estimates AC Immune Q3 EPS $(0.16) Beats $(0.22) Estimate, Sales $3.994M Beat $1.000M Estimate
AC Immune Third Quarter 2026 Financial and Corporate Update
Best Momentum Stock to Buy for September 30th
AC Immune Parkinson's Vaccine Study Meets Safety, Immunogenicity Goals
AC Immune: Buy Continued ACI-7104 Progress, PD, And Pipeline Expansions
AC Immune Reports Positive Safety & Immunogenicity at week-100 in Part 1 of VacSYn Phase 2 Trial of ACI-7104
AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764
AC Immune (ACIU) Beats Q2 Earnings and Revenue Estimates
Your note
Sign in to keep a note on ACIU — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| BVF Inc. | 19.73% | 19,522,436 | 52.32M | Sep 29, 2024 |
| Blackrock Inc. | 2.70% | 2,674,311 | 7.17M | Sep 29, 2024 |
| Redmile Group, LLC | 1.71% | 1,694,167 | 4.54M | Sep 29, 2024 |
| Wells Fargo & Company | 1.12% | 1,108,038 | 2.97M | Sep 29, 2024 |
| Platinum Investment Management Ltd | 0.96% | 952,069 | 2.55M | Sep 29, 2024 |
| Renaissance Technologies, LLC | 0.65% | 646,007 | 1.73M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Funds-Health Sciences Opportunity Portfolio | 1.09% | 1,083,340 | 2.90M | Aug 30, 2024 |
| BlackRock Health Sciences Term Trust | 0.79% | 781,685 | 2.09M | Sep 29, 2024 |
| iShares Biotechnology ETF | 0.44% | 434,694 | 1.16M | Oct 30, 2024 |
| Alps ETF Tr-Alps Medical Breakthroughs ETF | 0.08% | 77,640 | 208.07K | Aug 30, 2024 |
| Blackrock Health Sciences Trust | 0.08% | 78,180 | 209.52K | Sep 29, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.06% | 58,296 | 156.23K | Oct 30, 2024 |
